IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roader who wrote (1386)	12/3/1997 9:01:00 PM
From: aknahow	of 1762

Respoanse by Rastetter, Chairman, Pres, & CEO of Idec Pharm to Nov 25 article re Rituxan & Bexxar. In Investors Business Daily 3 Dec. page A32. Very well done, conclusion was, .."for many reasons, comparing Rituxan and any radioimmunotherapy is like comparing an apple and an orange." Letter goe into all the interesting details of why. Don't forget if any of you on this thread find out the percent paid to Xoma as a royalty please post this info. Was pleased to note start of sales in Europe.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next